1.62 0.00 (0.00%)
After hours: 5:35PM EDT
|Bid||1.62 x 700|
|Ask||1.65 x 700|
|Day's Range||1.60 - 1.68|
|52 Week Range||0.73 - 2.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock
Shares of Novavax Inc. tumbled 16% in active premarket trade Thursday, after the biotechnology company said its relatively large public offering of stock priced at a deep discount. Volume topped 8.5 million ...
Details of the offering — including how many shares the company would sell, at what price, and when — are still being hammered out.
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.
Sorrento Therapeutics (SRNE) is a clinical-stage biotechnology company. Its research programs are targeted at autoimmune, inflammatory, and neurodegenerative diseases and pain indications. Essentially, Sorrento Therapeutics is an antibody-centric company and leverages its G-MAB library to generate product candidates.
AbbVie (ABBV) is a global biopharmaceutical company with a focus on research. AbbVie’s pipeline also includes medicines for cystic fibrosis and women’s health. Of the 23 analysts covering AbbVie in March 2018, four analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating.
In 2017, Xencor generated $31.9 million from investing activities compared to its expenditure of $213.6 million in 2016. The company’s investing activities mainly consist of the purchase and sale of marketable securities and the acquisition of intellectual property and equipment. In 2017, Xencor used $39.2 million in marketable securities.
Xencor’s proprietary technology platform, XmAb, enables it to create antibody product candidates for the treatment of autoimmune and allergic diseases. Of the six analysts covering Xencor in March 2018, three have given the stock “strong buy” ratings, and two have given it “buy” ratings, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.67, and its target price is $36.67.
Novavax Inc’s (NASDAQ:NVAX): Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The US$685.25MRead More...
How Is Novavax Positioned in 2018? Novavax (NVAX) vaccine candidates are engineered to elicit differentiated immune responses with a potential to provide increased protection. Novavax’s vaccine for respiratory syncytial virus (or RSV) is being developed for three target age groups.
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech ...
"These are results that advance both programs in their respective clinical trials and create momentum for our execution during the remainder of 2018 and beyond," Erck said in a conference call with analysts after the company released its fourth quarter and year-end financial results Wednesday evening. "There's no other product anywhere near us, and we're looking forward to having the first RSV vaccine," Erk said.